January 27th 2023
A ED screening program identified a substantial number of patients with undiagnosed prediabetes and T2D or undermanaged disease, particularly racial and ethnic minorities.
The uptake of modern glucose-monitoring technologies for people with T1D and T2D may be dependent on out-of-pocket costs, suggesting the need to reconsider cost-benefit profiles of these devices.
An analysis of a commercial claims database offers insight into the increase in vision-threatening eye disease among people with diabetes aged younger than 65 years from 2009-2018, with results also detailing trends in anti-VEGF therapy during the same period.
A study examining associations between coffee metabolites and risk of NAFLD severity suggests people with type 2 diabetes had a lower risk of fibrosis and more severe NAFLD based on increased coffee consumption.
Announced by Novo Nordisk on January 12, the label update from the FDA removes a previous indication stating oral semaglutide (Rybelsus) should not be used as an initial therapy, which clears the way for the agent to be used as a first-line therapy in type 2 diabetes.
Using data from the SEARCH for Diabetes in Youth study, a new analysis suggests rates of type 1 diabetes in youth may increase by 65% between now and 2060, while rates of type 2 diabetes could increase more than 600% during that same period if left unchecked.
Eight studies provided evidence to suggest the relationship between diabetes and the onset of frozen shoulder, but more high-quality cohort studies may be necessary to better understand the nature of the relationship.
Using data from 18 trials with more than 1400 participants, a systematic review and meta-analysis offer clinicians an overview of the effects of SGLT2 inhibitor use on body composition in people with type 2 diabetes.
Using data from more than 55,000 people with diabetes using metformin is providing new insight into the apparent reductions in risk of negative cardiovascular and renal outcomes as well as all-cause mortality with use of SGLT2 inhibitors.
Exploratory analyses of data from the Look AHEAD trial suggest maintaining an HbA1c level of 7% or less was associated with smaller increases in frailty index over the 8-year study period when compared to their counterparts with an HbA1c level of 8% or greater.
An expert endocrine clinical pharmacist and nurse practitioner discuss clinical trial data on how inhaled insulin affects glucose management in T1D and T2D.
Drs Diana Isaacs and Natalie Bellini share the FDA-approved patient populations for inhaled insulin use to manage diabetes, as well as who would not be a good candidate.
Drs Diana Isaacs and Natalie Bellini discuss the limitations of injectable insulins in achieving time-in-range and glucose targets in type 1 and type 2 diabetes.
Expert health care practitioners review the different types of insulin formulations available for people with T1D or T2D, including regular and rapid-acting.
Drs Diana Isaacs and Natalie Bellini discuss selecting the right insulin delivery method for patients with diabetes, and the challenges that arise with insulin injectables.
Drs Diana Isaacs and Natalie Bellini provide an overview of the types of insulin delivery systems used in type 1 diabetes (T1D) and type 2 diabetes (T2D), including injections, patches, and inhalable insulin.